Golden Helix: Empowering Precision Medicine through Next-Gen Technology

Andreas Scherer, President & CEO
The quest for Precision Medicine is creating a paradigm shift in the way health diagnosis and treatments are being carried out today. Precision Medicine allows for more accurate diagnosis and treatment by leveraging an individual’s genetic makeup, answering questions such as “What specific disease does this person have?”,“How does this person metabolize medications?”, and “What kind of treatment options are available based on the presence of specific genetic markers?” just to name a few. This shift extends to all facets of healthcare from research organizations to hospitals, testing laboratories, pharmaceutical companies and government organizations, bringing the challenge of managing, analyzing and cataloguing increasingly massive amounts of genetic data. To help overcome these challenges and empower Precision Medicine, Golden Helix, an analytics software company based in Bozeman, MT is putting its 17 years of experience with over 300 organizations in the industry to work.

Golden Helix’s SNP and Variation Suite (SVS) software empowers research organizations as well as pharmaceutical companies to perform the complex statistical analyses involved in genome-wide association studies and rare variant analysis in order to uncover the associations between diseases and underlying genetic markers. SVS allows this complex process to be executed simply and easily, by the researchers themselves, without requiring the support of a bioinformatics specialist drastically cutting the OPEX.

For hospitals and testing labs, where the impact of Precision Medicine is more direct. Golden Helix offers a clinical suite of products, which helps to speed up the process of analyzing large data-sets. This in turn allows clinicians to diagnose patients more effectively and to quickly select the most appropriate treatment options, based on genetic makeup. “VarSeq is proving to be a highly valued tool in the clinical testing market," said Andreas Scherer, President and CEO of Golden Helix. “VarSeq has helped testing labs like Prevention Genetics achieve their goal of offering exome testing by helping them to speed up the analysis of exome sequencing data.”

Precision medicine will fundamentally change how health care is practiced

At the suite’s core, is VarSeq which begins by providing a filtering and annotation engine to sift through large variant data sets, zeroing in on those that are most likely to be connected with the observed phenotype. After VarSeq provides the variants of interest; VarSeq Reports can be used to generate a fully customizable, clinical-grade report based on ACMG guidelines. In a high-throughput environment, the clinical pipeline can be automated by implementing VarSeq Pipeline. VarSeq Pipeline allows for the creation of workflow-encoded project templates in VarSeq, locking down quality control and filtering parameters, automating the entire pipeline and providing the lab with the requirements needed for a CLIA and CAP certified analysis. VarSeq projects produced by the automated pipeline can be used by lab staff to complete the variant interpretation and reporting using the easy-to-use graphical interface.

“Precision Medicine will fundamentally change how health care is practiced,” reflected Scherer. “We look forward to serving the evolving needs in this market.” In 2016 Golden Helix plans to launch its newest software solution, VSWarehouse. “VSWarehouse will provide the ability to store annotated variant data along with clinical reports, providing an annotation source for future clinical assessments as well as the basis for cohort studies,” commented Scherer. “This is a key capability for pharma companies which are generating vast amounts of data in this space.” The company’s new warehouse solution will also serve as an integration point to other IT systems in laboratories and hospitals.

Golden Helix News

For the 3rd Time, Golden Helix, Inc., Appears on the Inc. 5000, Ranking No. 3267

NEW YORK: magazine today revealed that Golden Helix, Inc. is No. 3267 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy's most dynamic segment—its independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

"This award is a testament to the dedication, ingenuity, and work ethics of the entire Golden Helix team. After numerous successful product launches in the clinical variant analysis space over the last three years, matched by an excellent execution of our go-to-market strategy, we are experiencing sustained growth in all key global markets," says Andreas Scherer, Ph.D., President & CEO of Golden Helix. "I would like to thank my entire team for this outstanding achievement. Also, I would like to thank our customers and partners for their loyalty and commitment to us as a company."

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at The top 500 companies are featured in the September issue of Inc., which will be available on newsstands on August 20.

"The 2021 Inc. 5000 list feels like one of the most important rosters of companies ever compiled," says Scott Omelianuk, editor-in-chief of Inc. "Building one of the fastest-growing companies in America in any year is a remarkable achievement. Building one in the crisis we've lived through is just plain amazing. This kind of accomplishment comes with hard work, smart pivots, great leadership, and the help of a whole lot of people."

Golden Helix

Bozeman, MT

Andreas Scherer, President & CEO

Helps genetic research groups working with large-scale DNA-sequencing or microarray data in overcoming the challenges of bioinformatics roadblocks

Golden Helix